ClinicalTrials.gg
CompletedNCT00306293Updated Mar 23, 2018Results posted

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

A Phase 4 interventional study of valacyclovir in Herpes Labialis, sponsored by GlaxoSmithKline. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-23.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Herpes Labialis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Herpes Labialis · United States.

Enrollment
21st of 29
70 · median 300
Started
2006
with 1 other
Phase 4
Only one
of the 30
Registered
4th of 30
by date

Among the 30 studies in Herpes Labialis with a site in United States, this one is the 21st largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2006, is the only one in phase 4, and was the 4th registered.

Herpes Labialis

53 studies on the registry are indexed under Herpes Labialis; 2 are open to participants now.

Browse Herpes Labialis studies →

Open to participants now

2 of the 30 studies in Herpes Labialis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Herpes Labialis studies recruiting now, none set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Herpes Labialis with a site in United States, or all of them as a file.
02

Study summary

Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.

03

Conditions studied

  • Herpes Labialis

Keywords

  • Recurrent Genital Herpes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is in overall general good health.
  • If female, subject must be of:

    1. Non- (i.e., physiologically incapable of becoming pregnant, including any female who is pre-menarchial or or surgically sterile); or
    2. Childbearing potential, but must have a negative pregnancy test at randomization, and must be compliant with one of the following: Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period of 1 week after study completion or premature discontinuation from the study (to account for elimination of the drug); Have a male partner who is confirmed to be sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; Use of (s) with a documented failure rate of less than 1% per year, including but not limited to: implants of levonorgestrel, use of injectable progestogen, oral contraceptives (either combined or progestogen only), an intrauterine device (IUD) or spermicide plus a mechanical barrier (condom/diaphragm).
  • Subjects must be newly diagnosed with a first recognized episode of genital herpes as described in (a) or (b) below (See Appendix 3): a.HSV-2 seropositive at screen, with documented clinical signs and symptoms consistent with genital herpes at screen or within 4 months prior to randomization or b.HSV-2 seronegative at screen, AND HSV-2 culture positive or HSV-2 PCR positive with documented clinical signs and symptoms consistent with genital herpes at screen or within 4 months prior to randomization.
  • Subject must be willing and able to provide written and comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject is known or suspected to be (e.g., subjects receiving immunosuppressive therapy or chemotherapy for , or are seropositive for ).
  • Subject received an drug in the 30 days prior to the randomization visit.
  • Subject is receiving systemic antiviral or immunomodulatory treatments.
  • Subjects who have received systemic antiherpetic treatments (e.g., valacyclovir, acyclovir, ganciclovir, famciclovir) within 3 days of starting study drug, or immunomodulatory treatments in the 30 days before starting study drug.
  • Subject has clinically significantly impaired renal function as defined by less than 50ml/min (calculated using the Cockcroft-Gault formula).
  • Subjects with a history or evidence of decompensated liver disease, or clinically significantly impaired hepatic function defined as an (alanine transaminase) level >3 times the normal upper limit.
  • Subject is known to be hypersensitive to valacyclovir, acyclovir, ganciclovir or famciclovir.
  • Subject has malabsorption or vomiting syndrome or other gastrointestinal dysfunction that may impair drug pharmacokinetics.
  • Female subject who is contemplating pregnancy within the duration of the study drug dosing period.
  • Female subject who is pregnant and/or nursing.
  • Subject with current alcohol or drug abuse.
  • Subjects who have received suppressive (daily) therapy for genital herpes prior to randomization. Suppressive therapy is defined as daily antiherpetic therapy of at least 4 weeks duration.
  • Subjects with a history of ocular HSV (herpes simplex virus) infection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Days of Total Shedding (Clinical and Subclinical) as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for Herpes Simplex Virus Type 2 (HSV-2)

    Each participant's study day were classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab are positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Percent of days with HSV-2 shedding was defined for each participant as the percent of days with PCR data for which HSV-2 shedding was detected by a positive PCR result, i.e., the number of days with HSV-2 PCR shedding divided by total number of days with PCR data, multiplied by 100. Sum of the percent clinical and nonclinical shedding days was reported as total shedding. Mean percent of days with HSV-2 shedding was reported for each treatment group.

    Time frame: Up to 60 days in each treatment period (Up to 148 days)

Secondary outcomes

  1. Mean Percent Days Subclinical Shedding (no Genital Lesions Present)

    The percent of days with subclinical HSV-2 shedding was defined as the percent of all days with PCR data for which subclinical HSV-2 shedding was detected (shedding in the absence of a genital lesion). Mean percent of days with subclinical HSV-2 shedding was reported for each treatment group. Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits.

    Time frame: Up to 60 days in each treatment period (Up to 148 days)

  2. Mean Percent Days Clinical Shedding (Presence of Genital Lesions)

    The percent of days with clinical HSV-2 shedding was defined as the percent of all days with PCR data for which clinical HSV-2 shedding was detected (shedding in the presence of a genital lesion). Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Mean percent of days with clinical HSV-2 shedding was reported for each treatment group.

    Time frame: Up to 60 days in each treatment period (Up to 148 days)

  3. Percentage of Participants With no Shedding

    The proportion of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data in the Treatment Period. Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Mean percent of days with no shedding was reported for each treatment group.

    Time frame: Up to 60 days in each treatment period (Up to 148 days)

  4. Percentage of Participants With at Least One Genital Herpes Recurrence

    The proportion of participants with at least one genital herpes recurrence was defined as the number of participants with at least one investigator-confirmed genital herpes recurrence divided by the total number of participants with at least one clinic visit in the treatment period.

    Time frame: Up to 60 days in each treatment period (Up to 148 days)

  5. Median Time to First Genital Herpes Recurrence (Days)

    Time to first genital herpes recurrence was evaluated using Kaplan-Meier estimates of investigator-confirmed genital herpes recurrences censoring the data from participants who prematurely discontinue the study at the time of discontinuation.

    Time frame: Up to Day 68

  6. Number of Participants With Any Adverse Event (AE) and Serious Adverse Event (SAE)

    AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include adverse events that result in death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. No SAEs were reported in this study.

    Time frame: Up to 148 days

07

Results

Posted Mar 23, 2018

Participant flow

Seventy participants were enrolled at 14 centers in the United States. The study was conducted between 20 February 2006 and 28 November 2006.

Period 1 (Day 1 to Day 60)
Participant flow — Period 1 (Day 1 to Day 60)
MilestoneVALTREX 1 g First Then PlaceboPlacebo First Then VALTREX 1 g
Started3535
Completed2727
Not completed88
Withdrew: Adverse event10
Withdrew: Lost to follow-up34
Withdrew: Withdrawal by subject22
Withdrew: Positive pregnancy test22
Washout (Day 61 to Day 66)
Participant flow — Washout (Day 61 to Day 66)
MilestoneVALTREX 1 g First Then PlaceboPlacebo First Then VALTREX 1 g
Started2727
Completed2727
Not completed00
Period 2 (Day 67 to Day 126 )
Participant flow — Period 2 (Day 67 to Day 126 )
MilestoneVALTREX 1 g First Then PlaceboPlacebo First Then VALTREX 1 g
Started2727
Completed2426
Not completed31
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Participant determined hsv-2 negative01
Withdrew: Pregnancy10

Outcome measures

PrimaryMean Percent Days of Total Shedding (Clinical and Subclinical) as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for Herpes Simplex Virus Type 2 (HSV-2)

Each participant's study day were classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab are positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Percent of days with HSV-2 shedding was defined for each participant as the percent of days with PCR data for which HSV-2 shedding was detected by a positive PCR result, i.e., the number of days with HSV-2 PCR shedding divided by total number of days with PCR data, multiplied by 100. Sum of the percent clinical and nonclinical shedding days was reported as total shedding. Mean percent of days with HSV-2 shedding was reported for each treatment group.

Time frame:
Up to 60 days in each treatment period (Up to 148 days)
Reported as:
Mean · Percent of days
Mean Percent Days of Total Shedding (Clinical and Subclinical) as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for Herpes Simplex Virus Type 2 (HSV-2)
Percent of daysVALTREX 1 g, ODPlacebo
Mean Percent Days of Total Shedding (Clinical and Subclinical) as Determined by Type-specific Polymerase Chain Reaction (PCR) Assay for Herpes Simplex Virus Type 2 (HSV-2)2.9 ± 5.613.5 ± 16.9
SecondaryMean Percent Days Subclinical Shedding (no Genital Lesions Present)

The percent of days with subclinical HSV-2 shedding was defined as the percent of all days with PCR data for which subclinical HSV-2 shedding was detected (shedding in the absence of a genital lesion). Mean percent of days with subclinical HSV-2 shedding was reported for each treatment group. Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits.

Time frame:
Up to 60 days in each treatment period (Up to 148 days)
Reported as:
Mean · Percentage of days
Mean Percent Days Subclinical Shedding (no Genital Lesions Present)
Percentage of daysVALTREX 1 g, ODPlacebo
Mean Percent Days Subclinical Shedding (no Genital Lesions Present)2.4 ± 4.811 ± 15.1
Statistical analysis
  • VALTREX 1 g, OD vs Placebo · Wilcoxon Rank Sum Test · p = <0.001 · Percent change from placebo: -78Percent change in days with Subclinical HSV-2 Viral Shedding after VALTREX 1g treatment from the placebo
SecondaryMean Percent Days Clinical Shedding (Presence of Genital Lesions)

The percent of days with clinical HSV-2 shedding was defined as the percent of all days with PCR data for which clinical HSV-2 shedding was detected (shedding in the presence of a genital lesion). Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Mean percent of days with clinical HSV-2 shedding was reported for each treatment group.

Time frame:
Up to 60 days in each treatment period (Up to 148 days)
Reported as:
Mean · Percentage of Days
Mean Percent Days Clinical Shedding (Presence of Genital Lesions)
Percentage of DaysVALTREX 1 g, ODPlacebo
Mean Percent Days Clinical Shedding (Presence of Genital Lesions)0.6 ± 1.72.4 ± 4.4
Statistical analysis
  • VALTREX 1 g, OD vs Placebo · Wilcoxon Rank Sum · p = 0.014 · Percent change from baseline: -77Percent change in 'percentage of days with clinical HSV-2 viral shedding', after VALTREX 1g treatment from the placebo
SecondaryPercentage of Participants With no Shedding

The proportion of participants with no shedding was defined as the number of participants with no HSV-2 shedding detected by PCR divided by the total number of participants with PCR data in the Treatment Period. Each participant's study day was classified as either 'shedding' (positive HSV-2 result), 'no shedding' (negative HSV-2 result), or 'unknown' (swabbing not done or assay result not available) confirmed by PCR. If either the daily genital swab or a lesion swab was positive, the day was classified as 'shedding'. Study shedding day was classified as either 'clinical' (investigator-confirmed presence of genital lesions) or 'subclinical' (no genital lesions) by the investigator during recurrence visits. Mean percent of days with no shedding was reported for each treatment group.

Time frame:
Up to 60 days in each treatment period (Up to 148 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With no Shedding
Percentage of participantsVALTREX 1 g, ODPlacebo
Percentage of Participants With no Shedding6029
SecondaryPercentage of Participants With at Least One Genital Herpes Recurrence

The proportion of participants with at least one genital herpes recurrence was defined as the number of participants with at least one investigator-confirmed genital herpes recurrence divided by the total number of participants with at least one clinic visit in the treatment period.

Time frame:
Up to 60 days in each treatment period (Up to 148 days)
Reported as:
Number · Percetage of participants
Percentage of Participants With at Least One Genital Herpes Recurrence
Percetage of participantsVALTREX 1 g, ODPlacebo
Percentage of Participants With at Least One Genital Herpes Recurrence2148
SecondaryMedian Time to First Genital Herpes Recurrence (Days)

Time to first genital herpes recurrence was evaluated using Kaplan-Meier estimates of investigator-confirmed genital herpes recurrences censoring the data from participants who prematurely discontinue the study at the time of discontinuation.

Time frame:
Up to Day 68
Reported as:
Median · Days
Median Time to First Genital Herpes Recurrence (Days)
DaysVALTREX 1 g First Then PlaceboPlacebo First Then VALTREX 1 g
Median Time to First Genital Herpes Recurrence (Days)NA (11 to NA)61 (4 to 61)
SecondaryNumber of Participants With Any Adverse Event (AE) and Serious Adverse Event (SAE)

AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include adverse events that result in death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. No SAEs were reported in this study.

Time frame:
Up to 148 days
Reported as:
Count of participants · Participants
Number of Participants With Any Adverse Event (AE) and Serious Adverse Event (SAE)
ParticipantsVALTREX 1 g, ODPlacebo
Any AE1926
Any SAE00

Adverse events

Collected over AE and SAE were collected from randomization visit (Day 1) until the recurrence visit (Day 148). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VALTREX 1 g, OD0/62 (0%)0/62 (0%)19/62 (30.6%)
Placebo0/62 (0%)0/62 (0%)26/62 (41.9%)
Most frequent other events
Showing 10 of 54
Most frequent other events
EventVALTREX 1 g, ODPlacebo
Fungal infectionInfections and infestations3/626/62
Upper respiratory tract infectionInfections and infestations3/621/62
SinusitisInfections and infestations2/621/62
Vaginitis bacterialInfections and infestations2/621/62
BronchitisInfections and infestations2/620/62
Ear infectionInfections and infestations2/620/62
Vulvovaginal mycotic infectionInfections and infestations2/620/62
Vulvovaginitis trichomonalInfections and infestations0/622/62
ContusionInjury, poisoning and procedural complications0/622/62
DiarrhoeaGastrointestinal disorders1/622/62

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Overall Study
Mean30.9 ± 9.64
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female49
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
African American/African Heritage28
American Indian or Alaska Native2
Asian - East Asian Heritage2
White - Arabic/North African Heritage1
White - White/Caucasian/European Heritage36
Mixed Race1
08

Study locations

18 sites
  • GSK Investigational Site
    Anaheim, California 92805, United States
  • GSK Investigational Site
    Carmichael, California 95608, United States
  • GSK Investigational Site
    Fair Oaks, California 95628, United States
  • GSK Investigational Site
    Sacramento, California 95816, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33437, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33710, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    South Bend, Indiana 46601, United States
  • GSK Investigational Site
    Portage, Michigan 49024, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Memphis, Tennessee 38104, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2006 to primary completion in Nov 2006, 9 months.

Results were first posted in Mar 2018, 11 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2006
First posted
Mar 23, 2006
StartActual
Feb 20, 2006
Primary completionActual
Nov 27, 2006
CompletionActual
Nov 27, 2006
Results first posted
Mar 23, 2018
Last update
Mar 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00306293
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 23, 2006
Start date
Feb 20, 2006
Primary completion
Nov 27, 2006
Completion
Nov 27, 2006
Results posted
Mar 23, 2018
Last update
Mar 23, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion